Abstract:Macrophages are a promising target for drug delivery to influence macrophage-associated processes in the body, namely due to the presence of resistant microorganisms in macrophages. In this work, a series of mannosylated carriers based on mannan, polyethylenimine (PEI) and cyclodextrin (CD) was synthesized. The molecular architecture was studied using FTIR and 1H NMR spectroscopy. The particle size, from small 10–50 nm to large 500 nm, depending on the type of carrier, is potentially applicable for the creation of various medicinal forms: intravenous, oral and inhalation. Non-specific capture by cells with a simultaneous increase in selectivity to CD206+ macrophages was achieved. ConA was used as a model mannose receptor, binding galactosylated (CD206 non-specific) carriers with constants of the order of 104 M−1 and mannosylated conjugates of 106–107 M−1. The results of such primary “ConA-screening” of ligands are in a good agreement in terms of the comparative effectiveness of the interaction of ligands with the CD206+ macrophages: non-specific (up to 10%) absorption of highly charged and small particles; weakly specific uptake of galactosylated polymers (up to 50%); and high affine capture (more than 70–80%) of the ligands with grafted trimannoside was demonstrated using the cytometry method. Double and multi-complexes of antibacterials (moxifloxacin with its adjuvants from the class of terpenoids) were proposed as enhanced forms against resistant pathogens. In vivo pharmacokinetic experiments have shown that polymeric carriers significantly improve the efficiency of the antibiotic: the half-life of moxifloxacin is increased by 2–3 times in conjugate-loaded forms, bio-distribution to the lungs in the first hours after administration of the drug is noticeably greater, and, after 4 h of observation, free moxifloxacin was practically removed from the lungs of rats. Although, in polymer systems, its content is significant—1.2 μg/g. Moreover, the importance of the covalent crosslinking carrier with mannose label was demonstrated. Thus, this paper describes experimental, scientifically based methods of targeted drug delivery to macrophages to create enhanced medicinal forms.

Rifampicin Loaded Mannosylated Cationic Nanostructured Lipid Carriers for Alveolar Macrophage-specific Delivery

Mannose-Decorated Solid-Lipid Nanoparticles for Alveolar Macrophage Targeted Delivery of Rifampicin

Enhanced rifampicin delivery to alveolar macrophages by solid lipid nanoparticles

Preparation of Rifampicin - Solid Lipid Nanoparticles and Evaluation of Their Cell Specificity

Mannosylated solid lipid nanoparticles for the selective delivery of rifampicin to macrophages

An aerosol nanocomposite microparticle formulation using rifampicin-cyclodextrin inclusion complexes for the treatment of pulmonary diseases

Promising Chitosan-Coated Alginate-Tween 80 Nanoparticles as Rifampicin Coadministered Ascorbic Acid Delivery Carrier Against Mycobacterium tuberculosis

Quantification of rifampicin loaded into inhaled polymeric nanoparticles by reversed phase high-performance liquid chromatography in pulmonary nonphagocytic cellular uptake

Encapsulation of Rifampicin in Solid Lipid Nanoparticles by Microwave‐Assisted Microemulsion Method

Long-acting Antituberculous Therapeutic Nanoparticles Target Macrophage Endosomes.

The relevancy of controlled nanocrystallization on rifampicin characteristics and cytotoxicity

Mannan-Modified Solid Lipid Nanoparticles for Targeted Gene Delivery to Alveolar Macrophages

Preparation and characterization of rifampicin-PLGA microspheres/sodium alginate in situ gel combination delivery system.

Cascade‐Targeting Poly(amino acid) Nanoparticles Eliminate Intracellular Bacteria via On‐Site Antibiotic Delivery

Enhancing the Cellular Uptake and Antibacterial Activity of Rifampicin through Encapsulation in Mesoporous Silica Nanoparticles

Polyethylene Imine Conjugated Supramolecular Stereocomplexed Nanomicelles for Intracellular Delivery of Rifampicin Against Mycobacterium Bovis.

Drug-in-cyclodextrin-in-polymeric nanoparticles: A promising strategy for rifampicin administration

Rifampicin‐Loaded Nano‐In‐Microparticles (Trojan Particles) As A Pulmonary Delivery System For Tuberculosis Treatment

Development of a novel rapamycin loaded nano- into micro-formulation for treatment of lung inflammation

A Rigid Nanoplatform for Precise and Responsive Treatment of Intracellular Multidrug-Resistant Bacteria

Mannosylated Systems for Targeted Delivery of Antibacterial Drugs to Activated Macrophages